Bruker Daltonics and Serva Electrophoresis Announce Co-Marketing Agreement on ICPL Protein Quantitation Technology for Proteomic
06 June 2005 - 9:00PM
Business Wire
At the 2005 ASMS Conference, Bruker Daltonics Inc. and Serva
Electrophoresis GmbH today announce their new co-marketing
agreement, and present the ICPL(TM) stable isotope labeling
technology developed by Drs. Friedrich Lottspeich and Josef
Kellermann at the Max-Planck-Institute of Biochemistry in
Martinsried, Germany. The novel Isotope Coded Protein Label (ICPL)
technology enables true quantitation of differentially expressed
proteins with an unmatched dynamic range due to the optional
combination with intact protein fractionation steps. In contrast to
other isotope labeling approaches, the ICPL labeling step is not
limited to the peptide level but was developed to be applied on the
protein level. For complex proteomes, the complexity of the
resulting peptide mixtures typically exceeds the capacity of 1D or
2D peptide chromatographic steps and requires reduction of
complexity. As a unique feature, ICPL allows such reduction of
complexity on the protein level by chromatographic or other
fractionation steps without any sacrifice on quantitation accuracy.
All lysine side chains are modified by the ICPL tag, introducing a
mass difference of 6 Da per labeled site. Multiple peptides from
each protein usually carry the ICPL-tags after proteolysis which
allows robust statistics. The ICPL chemistry even leads to the
detection of modified peptides with increased sensitivity in MS.
The ICPL workflow is compatible with all established LC- or
gel-based protein and peptide fractionation and separation
techniques, and with all mass spectrometer types on the market
including ion traps. Protein identification and quantitation can be
obtained after protein digestion either with ESI-MS/MS on Bruker
Daltonics HCTultra ion trap or micrOTOF-Q Q-q-TOF system, or using
MALDI-MS/MS on the ultraflex II TOF/TOF. ICPL-based quantitative
analysis is fully supported by Bruker Daltonics' PROTEINEER-LC 1.1
suite providing automated analysis and data validation. Through the
co-marketing agreement between Bruker Daltonics and SERVA, the
SERVA ICPL kit can now be obtained worldwide from Bruker Daltonics.
Dr. Detlev Suckau, Head of proteomics development at Bruker
Daltonics, stated: "We consider the new ICPL labeling technology a
breakthrough for true quantitation in proteomics and biomarker
discovery. For the first time, entire proteomes can be analyzed
quantitatively and on solid statistical grounds. The bioinformatics
packages within our PROTEINEER-LC 1.1 suite will help our customers
to run ICPL analyses very conveniently in order to obtain validated
data quickly. The ICPL kits represent a great step forward towards
high-content proteomics in combination with our outstanding
LC-MS/MS instrumentation. We are very pleased and look forward to a
productive collaboration with Serva Electrophoresis GmbH." Barbara
Mueller of SERVA Electrophoresis GmbH, Heidelberg, said: "SERVA is
a leading supplier of electrophoresis specialty products, and is
the exclusively licensed distributor of the unique ICPL kits. Under
the co-marketing agreement with Bruker Daltonics, new avenues of
application are expected with a clear benefit to the proteomics
community." ICPL Inventor Professor Friedrich Lottspeich commented:
"Key to the success of proteomics technology is that quantitative
information on proteins can be obtained fast and reliably with a
high dynamic range in order to access low abundant proteins. These
are typically the proteins that matter. That absolutely requires
the proteome fractionation on the protein level and not only on the
peptide level. The ICPL technology was designed to provide reliable
quantitation due to data redundancy and the compatibility with any
combination of protein fractionation technologies, including 1D or
2D gel electrophoresis or protein LC. I am delighted that this
powerful technology will now be made available to the scientific
community." ABOUT SERVA ELECTROPHORESIS GMBH SERVA Electrophoresis
GmbH is an independent company with offices in Heidelberg and
Uetersen, Germany. SERVA is committed to supply top quality
reagents and specialty products through a global distribution
network. Our mission is to provide innovative products for protein
analytics and proteome research originating from know-how in
electrophoresis available at SERVA for decades, and through
collaborations with partners. SERVA's commitment is to adapt to the
changing needs of protein scientists while providing consistent
product quality under its ISO 9001:2000 certification. ABOUT BRUKER
BIOSCIENCES (NASDAQ: BRKR) Bruker BioSciences Corporation,
headquartered in Billerica, Massachusetts, is the publicly traded
parent company of Bruker Daltonics Inc. and Bruker AXS Inc. Bruker
AXS is a leading developer and provider of life science and
advanced materials research tools based on x-ray technology. Bruker
Daltonics is a leading developer and provider of innovative life
science tools based on mass spectrometry. Bruker Daltonics also
offers a broad line of nuclear, biological and chemical (NBC)
detection systems for homeland security. For more information:
www.bruker-biosciences.com CAUTIONARY STATEMENT OF BRUKER
BIOSCIENCES Any statements contained in this press release that do
not describe historical facts may constitute forward-looking
statements as that term is defined in the Private Securities
Litigation Reform Act of 1995. Any forward-looking statements
contained herein are based on current expectations, but are subject
to a number of risks and uncertainties. The factors that could
cause actual future results to differ materially from current
expectations include, but are not limited to, risks and
uncertainties relating to the Company's reorganization strategies,
integration risks, failure of conditions, technological approaches,
product development, market acceptance, cost and pricing of the
Company's products, changes in governmental regulations, capital
spending and government funding policies, FDA and other regulatory
approvals to the extent applicable, competition, the intellectual
property of others, patent protection and litigation. These and
other factors are identified and described in more detail in our
filings with the SEC, including, without limitation, our annual
report on Form 10-K for the year ended December 31, 2004, our most
recent quarterly reports on Form 10-Q and our current reports on
Form 8-K. We disclaim any intent or obligation to update these
forward-looking statements.
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Sep 2024 to Oct 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Oct 2023 to Oct 2024